“This collaboration represents yet another important disease biomarker discovery program for Caprion,” noted Dr Daniel Chelsky, chief scientific officer of Caprion Pharmaceuticals. “This study reflects how Caprion’s biomarker discovery capability addresses many key pharmaceutical needs, including predicting efficacy and safety and managing treatment progression.”
Caprion is also working with Pfizer and Wyeth, who recently expanded collaboration with Caprion to include applications in two clinical trials.